NCI

Alessa Therapeutics Announces First Patient Enrollment in Biolen®+RT Study with National Cancer Institute SAN CARLOS, CALIFORNIA, US, February 23, 2022 /EINPresswire.com/   Alessa Therapeutics, Inc., a clinical-stage drug development company developing an innovative and proprietary localized drug delivery technology to treat prostate disease, announced the enrollment of the first two men with prostate cancer in…

Alessa Therapeutics Announces Research Collaboration with Janssen SAN CARLOS, CALIFORNIA, US, October 11, 2021 /EINPresswire.com/   Alessa Therapeutics, Inc., a clinical-stage drug development company developing implantable drug delivery systems focused on sustained delivery of drugs to solid organ tumors, announced that it has entered into a research collaboration agreement with an affiliate of Janssen Research & Development,…

Alessa Therapeutics Announces IND Clearance for a Study in Collaboration with the National Cancer Institute SAN CARLOS, CALIFORNIA, US, June 7, 2021 /EINPresswire.com/   Alessa Therapeutics, Inc., a clinical-stage drug development company developing an innovative and proprietary localized drug delivery technology for the treatment of prostate disease, announced that the U.S. Food and Drug Administration…